Idera Pharmaceuticals, Inc. (IDRA) Social Stream



Idera Pharmaceuticals, Inc. (IDRA): $7.23

1.99 (-21.57%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add IDRA to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#260 of 465

in industry

IDERA PHARMACEUTICALS INC (IDRA) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering IDERA PHARMACEUTICALS INC.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-03-19 1 $2 $2 $2 $0.542 269%

Price Target Last Issued March 19, 2021

500 - Internal server error

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential

IDRA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3 0 0 1 0 0 1

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • IDRA has a higher number of analysts covering the stock than just about none of of all US stocks.
  • To contextualize these metrics, consider that out of all US stocks, IDERA PHARMACEUTICALS INC's variance in analysts' estimates is lower than almost 100% of them.
  • In terms of how IDERA PHARMACEUTICALS INC fares relative to Healthcare stocks, note that its average analyst price target is higher than 1.07% of that group.
  • In terms of how IDERA PHARMACEUTICALS INC fares relative to stocks in the small market cap category, note that its upside potential (average analyst target price relative to current price) is higher than 71.03% of that group.

Stocks similar to IDERA PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CVM, VXRT, and CRBU.

Is IDRA a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!